666 related articles for article (PubMed ID: 27558467)
1. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.
Fujinaga S; Hirano D; Mizutani A; Sakuraya K; Yamada A; Sakurai S; Shimizu T
Clin Exp Nephrol; 2017 Aug; 21(4):671-676. PubMed ID: 27558467
[TBL] [Abstract][Full Text] [Related]
2. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K
BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab.
Kamei K; Ogura M; Sato M; Sako M; Iijima K; Ito S
Pediatr Nephrol; 2016 Jan; 31(1):89-95. PubMed ID: 26341251
[TBL] [Abstract][Full Text] [Related]
4. Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome.
Hogan J; Dossier C; Kwon T; Macher MA; Maisin A; Couderc A; Niel O; Baudouin V; Deschênes G
Pediatr Nephrol; 2019 Feb; 34(2):253-259. PubMed ID: 30109447
[TBL] [Abstract][Full Text] [Related]
5. Positive role of rituximab in switching from cyclosporine to mycophenolate mofetil for children with high-dose steroid-dependent nephrotic syndrome.
Fujinaga S; Sakuraya K; Yamada A; Urushihara Y; Ohtomo Y; Shimizu T
Pediatr Nephrol; 2015 Apr; 30(4):687-91. PubMed ID: 25576066
[TBL] [Abstract][Full Text] [Related]
6. Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome.
Ito S; Kamei K; Ogura M; Udagawa T; Fujinaga S; Saito M; Sako M; Iijima K
Pediatr Nephrol; 2013 Feb; 28(2):257-64. PubMed ID: 23052656
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.
Kamei K; Ishikura K; Sako M; Aya K; Tanaka R; Nozu K; Kaito H; Nakanishi K; Ohtomo Y; Miura K; Takahashi S; Morimoto T; Kubota W; Ito S; Nakamura H; Iijima K;
Pediatr Nephrol; 2017 Nov; 32(11):2071-2078. PubMed ID: 28664242
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of Japanese children with complicated minimal change nephrotic syndrome treated with mycophenolate mofetil after cyclosporine.
Fujinaga S; Hirano D; Nishino T; Umeda C; Watanabe Y; Nakagawa M
Pediatr Nephrol; 2019 Nov; 34(11):2417-2421. PubMed ID: 31435725
[TBL] [Abstract][Full Text] [Related]
9. Predictive factors of long-term disease remission after rituximab administration in patients with childhood-onset complicated steroid-dependent nephrotic syndrome: a single-center retrospective study.
Ohyama R; Fujinaga S; Sakuraya K; Hirano D; Ito S
Clin Exp Nephrol; 2023 Oct; 27(10):865-872. PubMed ID: 37477752
[TBL] [Abstract][Full Text] [Related]
10. Rituximab and low-dose cyclosporine combination therapy for steroid-resistant focal segmental glomerulosclerosis.
Suyama K; Kawasaki Y; Miyazaki K; Kanno S; Ono A; Suzuki Y; Ohara S; Hosoya M
Pediatr Int; 2016 Mar; 58(3):219-223. PubMed ID: 26275234
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate Mofetil after Rituximab for Childhood-Onset Complicated Frequently-Relapsing or Steroid-Dependent Nephrotic Syndrome.
Iijima K; Sako M; Oba M; Tanaka S; Hamada R; Sakai T; Ohwada Y; Ninchoji T; Yamamura T; Machida H; Shima Y; Tanaka R; Kaito H; Araki Y; Morohashi T; Kumagai N; Gotoh Y; Ikezumi Y; Kubota T; Kamei K; Fujita N; Ohtsuka Y; Okamoto T; Yamada T; Tanaka E; Shimizu M; Horinochi T; Konishi A; Omori T; Nakanishi K; Ishikura K; Ito S; Nakamura H; Nozu K;
J Am Soc Nephrol; 2022 Feb; 33(2):401-419. PubMed ID: 34880074
[TBL] [Abstract][Full Text] [Related]
12. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.
Iijima K; Sako M; Nozu K; Mori R; Tuchida N; Kamei K; Miura K; Aya K; Nakanishi K; Ohtomo Y; Takahashi S; Tanaka R; Kaito H; Nakamura H; Ishikura K; Ito S; Ohashi Y;
Lancet; 2014 Oct; 384(9950):1273-81. PubMed ID: 24965823
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood--follow-up after CD19 recovery.
Sellier-Leclerc AL; Baudouin V; Kwon T; Macher MA; Guérin V; Lapillonne H; Deschênes G; Ulinski T
Nephrol Dial Transplant; 2012 Mar; 27(3):1083-9. PubMed ID: 21810762
[TBL] [Abstract][Full Text] [Related]
14. Novel use of rituximab for steroid-dependent nephrotic syndrome in children.
Kimata T; Hasui M; Kino J; Kitao T; Yamanouchi S; Tsuji S; Kaneko K
Am J Nephrol; 2013; 38(6):483-8. PubMed ID: 24296765
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and safety of common steroid-sparing agents in idiopathic nephrotic children.
Basu B; Babu BG; Mahapatra TK
Clin Exp Nephrol; 2017 Feb; 21(1):143-151. PubMed ID: 27108294
[TBL] [Abstract][Full Text] [Related]
16. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases.
Guigonis V; Dallocchio A; Baudouin V; Dehennault M; Hachon-Le Camus C; Afanetti M; Groothoff J; Llanas B; Niaudet P; Nivet H; Raynaud N; Taque S; Ronco P; Bouissou F
Pediatr Nephrol; 2008 Aug; 23(8):1269-79. PubMed ID: 18465150
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes after early treatment with rituximab for Japanese children with cyclosporine- and steroid-resistant nephrotic syndrome.
Fujinaga S; Nishino T; Umeda C; Tomii Y; Watanabe Y; Sakuraya K
Pediatr Nephrol; 2019 Feb; 34(2):353-357. PubMed ID: 30426219
[TBL] [Abstract][Full Text] [Related]
18. Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome.
Fujinaga S; Ozawa K; Sakuraya K; Yamada A; Shimizu T
Clin Nephrol; 2016 Jun; 85(6):340-5. PubMed ID: 27125626
[TBL] [Abstract][Full Text] [Related]
19. Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome.
Maxted AP; Dalrymple RA; Chisholm D; McColl J; Tse Y; Christian MT; Reynolds BC
Pediatr Nephrol; 2019 May; 34(5):855-863. PubMed ID: 30564878
[TBL] [Abstract][Full Text] [Related]
20. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome.
Ito S; Kamei K; Ogura M; Sato M; Fujimaru T; Ishikawa T; Udagawa T; Iijima K
Pediatr Nephrol; 2011 Oct; 26(10):1823-8. PubMed ID: 21556716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
